Ashleigh Furlong is a health care reporter at Bloomberg. She specializes in public health, pharmaceutical regulation, and consumer health, covering a wide range of topics including drugs and medication, immunology, and oncology. Ashleigh's work has been featured in prominent outlets such as Yahoo Finance, Scientific American, and TIME.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ashleigh Furlong's coverage spans a variety of topics, with a significant focus on healthcare and pharmaceutical issues. She places particular emphasis on government announcements, legal policy regulation, and breaking news.
Given her extensive coverage of healthcare and pharmaceutical matters, she may be interested in receiving pitches related to these areas. For instance, providing insights into recent health crises or developments in drug policies could resonate well with her area of expertise.
It is important to note that Ashleigh also covers international relations and conflicts such as the Middle East conflict and Russia-Ukraine conflict. Therefore, if your pitch relates to any evolving stories within these areas or includes relevant data citations from reputable sources, it might catch her attention.
Additionally, considering Ashleigh's frequent reference to government announcements and legal policy regulations in her coverage attributes suggests that she would likely appreciate pitches offering analysis or expert commentary on new legislative measures impacting the sectors she covers.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Women in England and Wales with a certain type of breast cancer may finally get access to a drug that could help them live longer.
By: Ashleigh Furlong
AstraZeneca and Ionis Pharmaceuticals Inc.’s gene silencer drug Wainua failed to help prevent heart problems in patients with a rare and potentially fatal disease of the organ. AstraZeneca’s shares slumped.
(Bloomberg) -- AstraZeneca and Ionis Pharmaceuticals Inc.'s gene silencer drug Wainua failed to help prevent heart problems in patients with a rare and potentially fatal disease of the organ.
(Bloomberg) -- AstraZeneca Plc suffered a rare setback in a trial of a new heart drug, surprising investors used to positive results from the UK drugmaker and sending its shares down almost 10%.
A trade deal with the US that increases the price Britain pays for new medicines will help patients and not cause hundreds of thousands of additional deaths, according to UK Technology Secretary Liz Kendall.
By: Amber Tong, Ashleigh Furlong
AstraZeneca Plc will pay China’s Dizal Jiangsu Pharmaceutical Co. $600 million upfront for global rights to a lung cancer drug, adding a commercial-ready treatment to its franchise amid a wave of deals from China.
By: Ashleigh Furlong, Lucca De Paoli
Consumers are being sold sexually transmitted disease test kits designed to be used by medical professionals, posing health risks.
By: Mark Bergen, Ashleigh Furlong
Neko Health, Daniel Ek’s startup developing body-scanning technology, has raised $700 million from venture capitalists, billionaires and celebrities to open new facilities, including one in New York later this year.
By: Ashleigh Furlong, Jason Gale
Frontline health workers in eastern Democratic Republic of Congo may soon be offered an experimental vaccine against the Bundibugyo strain of Ebola, as researchers test whether it can provide partial protection while a strain-specific vaccine remains months away.
By: Ashleigh Furlong, Lucca De Paoli
U-Test’s brand ambassadors aren’t medical professionals. The British company sells test kits for sexually transmitted infections, and bowel and prostate health over social media, so the faces of its business
